Invisible Light! Can the Treatment of Depression Be Beyond What is Seen?
Presenter: Paolo Cassano, MD, PhD
Transcranial photobiomodulation (t-PBM) with invisible near-infrared radiation (NIR) has emerged as a potential antidepressant treatment in both animal models and human studies. t-PBM consists of delivering NIR ─or red light─ to the scalp of the patient, which penetrates the skull and modulates function of the adjacent cortical areas of the brain. t-PBM with red light and/or NIR appears to increase brain metabolism (by activating the cytochrome C oxidase in the mitochondria), to increase neuroplasticity, and to modulate endogenous opioids, while decreasing inflammation and oxidative stress. t-PBM penetrates deeply into the cerebral cortex, modulates cortical excitability and improves cerebral perfusion and oxygenation. Studies have suggested that it can significantly improve cognition in healthy subjects, and in subjects with traumatic brain injury. The safety of t-PBM has been studied in a sample of acute 1,410 stroke patients, with no significant differences in rates of adverse events between t-PBM and sham exposure. Uncontrolled studies suggest an antidepressant effect of t-PBM in subjects suffering from major depressive disorder. A case on the use of t-PBM for the treatment of major depressive disorder will be presented, with discussion of evidence from a recent clinical trial.
- Review of Transcranial Photobiomodulation for Major Depressive Disorder: Targeting Brain Metabolism, Inflammation, Oxidativestress, and Neurogenesis– Paolo Cassano et al.
- Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study– Paolo Cassano et al.
Related News and Interviews
- Boston is on the verge of remarkable breakthroughs for our toughest medical conditions– Boston Globe | December, 2015
- New Treatment Trial Shines Light on Depression– CNN | January 2016
- Brain Hacking: Hot-wired for happiness?– Washington Post | March 2016
- New depression treatment using low-level light showing promise, needs more study– WCVB Channel 5 News | March 2016
Date: Tuesday, July 3rd, 2018
Time: 8:00 am – 9:00 am (followed by Coffee Hour)
Venue: Bornstein Family Amphitheater, BWH
Address: 45 Francis Street, Boston, MA 02115
Paolo Cassano MD, PhD
Assistant Professor of Psychiatry, Harvard Medical School
Director of Photobiomodulation
Depression Clinical and Research Program
Center for Anxiety and Traumatic Stress Disorders
Massachusetts General Hospital
Biography: Dr. Paolo Cassano is assistant professor of psychiatry at Harvard Medical School and director of photobiomodulation at the Massachusetts General Hospital (MGH) Depression and Clinical Research Program and at the MGH Center for Anxiety and Traumatic Stress Disorders.
Dr. Cassano received both his MD in medicine and surgery, and his PhD in clinical neuro-psychopharmacology from the University of Pisa in Italy. He pursued post-doctoral studies in mood and anxiety disorders with the MGH Depression and Clinical Research Program (DCRP) and graduated from the MGH-McLean Adult Psychiatry Residency Program in 2009.
Dr. Cassano’s research has focused on developing new treatments for major depressive disorder (MDD) and better characterizing response to treatment by examining comorbid conditions, cultural factors and trauma. During his PhD studies in Italy, he co-led several research projects focusing on the use of two anti-Parkinson drugs for the treatment of resistant-depression. After coming to the United States he joined the DCRP at MGH, where he continued to study mood disorders, comorbidity and resistance to treatment as a co-investigator in STAR*D ─ the Sequenced Treatment Alternatives to Relieve Depression ─ trial.
Since 2014, Dr. Cassano has held a dual appointment at the MGH Center for Anxiety and Traumatic Stress Disorders (CATSD) and DCRP. At the DCRP and at the CATSD, he has severed as principal investigators and co-investigators on multiple studies on Major Depressive Disorder, PTSD, Generalized Anxiety Disorder (GAD) and Social Anxiety Disorder.
Since 2009, he has served as principal investigator on several studies on transcranial photobiomodulation for MDD, GAD and in healthy subjects, including a Brain and Behavior Research Foundation (2012 NARSAD YI) Award and a Dupont Warren/Livingston Fellowship from Harvard Medical School. These groundbreaking projects ─ in collaboration with the MGH Wellman Center for Photomedicine ─ have led to very promising results. Considerable press attention stemmed from these studies, with CNN and Washington Post coverage at the national level.